{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:54:17Z","timestamp":1794254057185,"version":"4.9.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01458-2","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:46:00Z","timestamp":1773110760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current treatment algorithm: diffuse large B cell lymphoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"1458_CR1","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"1458_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"1458_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298\u2013310.","journal-title":"Lancet"},{"key":"1458_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"1458_CR5","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121\u20137.","journal-title":"J Clin Oncol"},{"key":"1458_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"1458_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","volume":"105","author":"S Monti","year":"2005","unstructured":"Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851\u201361.","journal-title":"Blood"},{"key":"1458_CR8","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1458_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"1458_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363.","journal-title":"N Engl J Med"},{"key":"1458_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P.","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"1458_CR12","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","volume":"36","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ, Ghesquieres H, Link BK, Jais JP, Habermann TM, Thompson CA, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36:1603\u201310.","journal-title":"J Clin Oncol"},{"key":"1458_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMc2306105","volume":"389","author":"AC Palmer","year":"2023","unstructured":"Palmer AC, Kurtz DM, Alizadeh AA. Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin. N Engl J Med. 2023;389:764\u20136.","journal-title":"N Engl J Med"},{"key":"1458_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"1458_CR15","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","volume":"114","author":"NA Johnson","year":"2009","unstructured":"Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114:2273\u20139.","journal-title":"Blood"},{"key":"1458_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.18.01583","volume":"37","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:190\u2013201.","journal-title":"J Clin Oncol"},{"key":"1458_CR17","first-page":"2493","volume":"141","author":"W Alduaij","year":"2023","unstructured":"Alduaij W, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, et al. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood. 2023;141:2493\u2013507.","journal-title":"Blood"},{"key":"1458_CR18","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","volume":"39","author":"WH Wilson","year":"2021","unstructured":"Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39:1643\u201353 e3.","journal-title":"Cancer Cell"},{"key":"1458_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70017","volume":"43","author":"P Zhao","year":"2025","unstructured":"Zhao P, Zhao S, Huang C, Li Y, Wang J, Xu J, et al. Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: a real-world, multi-center, retrospective cohort study. Hematol Oncol. 2025;43:e70017.","journal-title":"Hematol Oncol"},{"key":"1458_CR20","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","volume":"5","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5:e609\u2013e17.","journal-title":"Lancet Haematol"},{"key":"1458_CR21","first-page":"448","volume":"110","author":"SA Atallah-Yunes","year":"2025","unstructured":"Atallah-Yunes SA, Rees MJ, Witzig TE, Habermann TM, Munoz J, Iqbal M, et al. CODOX-M\/IVAC-R versus DA-EPOCH-R in double-hit\/triple-hit lymphoma patients aged 60 years or under. Haematologica. 2025;110:448\u201356.","journal-title":"Haematologica"},{"key":"1458_CR22","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood. 1997;89:3909-18.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"1458_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clml.2023.09.006","volume":"24","author":"DA Ermann","year":"2024","unstructured":"Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, et al. Survival outcomes of limited-stage diffuse large B-cell lymphoma treated with radiation therapy. Clin Lymphoma Myeloma Leuk. 2024;24:94\u2013104.e6.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1458_CR24","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","volume":"34","author":"DM Stephens","year":"2016","unstructured":"Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group study S8736. J Clin Oncol. 2016;34:2997\u20133004.","journal-title":"J Clin Oncol"},{"key":"1458_CR25","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2019","unstructured":"Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271\u201381.","journal-title":"Lancet"},{"key":"1458_CR26","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.20.00999","volume":"38","author":"DO Persky","year":"2020","unstructured":"Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020;38:3003\u201311.","journal-title":"J Clin Oncol"},{"key":"1458_CR27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:1317\u201328.","journal-title":"J Clin Oncol"},{"key":"1458_CR28","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285\u201395.","journal-title":"J Clin Oncol"},{"key":"1458_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649\u201362.","journal-title":"Lancet Oncol"},{"key":"1458_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70110_LBA1","volume":"43","author":"E Calabretta","year":"2025","unstructured":"Calabretta E, Lu K, Zhao X, Stewart C, Palazzo M, Crombie JL, et al. LBA1|The benefit of pola-R-CHP in DLBclass-defined molecular subsets of newly diagnosed DLBCL in the Polarix trial. Hematol Oncol. 2025;43:eLBA1_70110.","journal-title":"Hematol Oncol"},{"key":"1458_CR31","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1182\/bloodadvances.2022007609","volume":"6","author":"V Camus","year":"2022","unstructured":"Camus V, Belot A, Oberic L, Sibon D, Ghesquieres H, Thieblemont C, et al. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Adv. 2022;6:6169\u201379.","journal-title":"Blood Adv"},{"key":"1458_CR32","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"1458_CR33","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333:1540\u20135.","journal-title":"N Engl J Med"},{"key":"1458_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389:148\u201357.","journal-title":"N Engl J Med"},{"key":"1458_CR35","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294\u2013308.","journal-title":"Lancet"},{"key":"1458_CR36","doi-asserted-by":"crossref","unstructured":"Chung A, Shafrin J, Vadgama S, Hurley K, Perales MA, Alsfeld LC, et al. Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed\/Refractory DLBCL: A SEER-Medicare Data Analysis. Blood Adv. 2025.","DOI":"10.1182\/bloodadvances.2024015634"},{"key":"1458_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u201354.","journal-title":"N Engl J Med"},{"key":"1458_CR38","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1200\/JCO-25-00399","volume":"43","author":"M Kamdar","year":"2025","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-Year follow-up from the randomized, phase III transform study. J Clin Oncol. 2025;43:2671\u20138.","journal-title":"J Clin Oncol"},{"key":"1458_CR39","doi-asserted-by":"crossref","unstructured":"Morimoto S, Jo T, Kitawaki T, Sakamoto T, Mizumoto C, Kanda J, et al. Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma. Br J Haematol. 2025.","DOI":"10.1111\/bjh.70090"},{"key":"1458_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41409-024-02427-8","volume":"60","author":"S Bramanti","year":"2025","unstructured":"Bramanti S, Mannina D, Chiappella A, Casadei B, De Philippis C, Giordano L, et al. Role of bridging RT in relapsed\/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study. Bone Marrow Transplant. 2025;60:32\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1458_CR41","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/bloodadvances.2023011489","volume":"8","author":"MD Jain","year":"2024","unstructured":"Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, et al. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024;8:1042\u201350.","journal-title":"Blood Adv"},{"key":"1458_CR42","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol"},{"key":"1458_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","volume":"71","author":"WS Velasquez","year":"1988","unstructured":"Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117\u201322.","journal-title":"Blood"},{"key":"1458_CR44","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","volume":"103","author":"T Kewalramani","year":"2004","unstructured":"Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684\u20138.","journal-title":"Blood"},{"key":"1458_CR45","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/cncr.20587","volume":"101","author":"M Crump","year":"2004","unstructured":"Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004;101:1835\u201342.","journal-title":"Cancer"},{"key":"1458_CR46","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.27630","volume":"100","author":"S Yamshon","year":"2025","unstructured":"Yamshon S, Koff JL, Larson MC, Kahl BS, Casulo C, Lossos IS, et al. Outcomes of relapsed or refractory diffuse large B-cell lymphoma treated with R-GemOx: a multicenter cohort study. Am J Hematol. 2025;100:606\u201315.","journal-title":"Am J Hematol"},{"key":"1458_CR47","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315.","journal-title":"Blood"},{"key":"1458_CR48","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143:404\u201316.","journal-title":"Blood"},{"key":"1458_CR49","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315.","journal-title":"Lancet Oncol"},{"key":"1458_CR50","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonzalez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978\u201388.","journal-title":"Lancet Oncol"},{"key":"1458_CR51","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790\u2013800.","journal-title":"Lancet Oncol"},{"key":"1458_CR52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","volume":"6","author":"LH Sehn","year":"2022","unstructured":"Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6:533\u201343.","journal-title":"Blood Adv"},{"key":"1458_CR53","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO-24-02242","volume":"43","author":"NL Bartlett","year":"2025","unstructured":"Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol. 2025;43:1061\u201372.","journal-title":"J Clin Oncol"},{"key":"1458_CR54","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220\u201331.","journal-title":"N Engl J Med"},{"key":"1458_CR55","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s43018-025-00941-2","volume":"6","author":"G Cartron","year":"2025","unstructured":"Cartron G, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, et al. Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study. Nat Cancer. 2025;6:1173\u201383.","journal-title":"Nat Cancer"},{"key":"1458_CR56","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38:2653\u201362.","journal-title":"Leukemia"},{"key":"1458_CR57","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-23-1962","volume":"30","author":"J Lownik","year":"2024","unstructured":"Lownik J, Boiarsky J, Birhiray R, Merchant A, Mead M. Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma. Clin Cancer Res. 2024;30:2895\u2013904.","journal-title":"Clin Cancer Res"},{"key":"1458_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024;14:27.","journal-title":"Blood Cancer J"},{"key":"1458_CR59","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","volume":"118","author":"C Steidl","year":"2011","unstructured":"Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118:2659\u201369.","journal-title":"Blood"},{"key":"1458_CR60","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.15051","volume":"180","author":"NN Shah","year":"2018","unstructured":"Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180:534\u201344.","journal-title":"Br J Haematol"},{"key":"1458_CR61","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408\u201316.","journal-title":"N Engl J Med"},{"key":"1458_CR62","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO-24-01373","volume":"42","author":"M Martelli","year":"2024","unstructured":"Martelli M, Ceriani L, Ciccone G, Ricardi U, Kriachok I, Botto B, et al. Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results. J Clin Oncol. 2024;42:4071\u201383.","journal-title":"J Clin Oncol"},{"key":"1458_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s44313-025-00076-4","volume":"60","author":"YP Lee","year":"2025","unstructured":"Lee YP, Cho J, Ko YH, Oh D, Kim SJ, Kim WS, et al. Real-world data analysis of survival outcomes of patients with primary mediastinal large B-cell lymphoma treated with immunochemotherapy: the role of consolidative radiation therapy. Blood Res. 2025;60:27.","journal-title":"Blood Res"},{"key":"1458_CR64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2023-181467","volume":"142","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142:141\u20135.","journal-title":"Blood"},{"key":"1458_CR65","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","volume":"29","author":"U Vitolo","year":"2011","unstructured":"Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766\u201372.","journal-title":"J Clin Oncol"},{"key":"1458_CR66","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/bloodadvances.2023011251","volume":"8","author":"A Conconi","year":"2024","unstructured":"Conconi A, Chiappella A, Ferreri AJM, Stathis A, Botto B, Sassone M, et al. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. Blood Adv. 2024;8:1541\u20139.","journal-title":"Blood Adv"},{"key":"1458_CR67","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20:687\u201394.","journal-title":"Neuro Oncol"},{"key":"1458_CR68","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ajh.25558","volume":"94","author":"C Perry","year":"2019","unstructured":"Perry C, Ben Barouch S, Goldschmidt N, Sarid N, Herishanu Y, Shvidel L, et al. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: a retrospective multicenter study. Am J Hematol. 2019;94:992\u20131001.","journal-title":"Am J Hematol"},{"key":"1458_CR69","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150\u20136.","journal-title":"J Clin Oncol"},{"key":"1458_CR70","doi-asserted-by":"crossref","unstructured":"Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, et al. Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024.","DOI":"10.1002\/hem3.89"},{"key":"1458_CR71","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","volume":"40","author":"C Houillier","year":"2022","unstructured":"Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molucon-Chabrot C, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study. J Clin Oncol. 2022;40:3692\u20138.","journal-title":"J Clin Oncol"},{"key":"1458_CR72","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/bloodadvances.2024014404","volume":"9","author":"ER Tolley","year":"2025","unstructured":"Tolley ER, Nielsen TH, Hersby DS, Ostergaard S, Rasmussen M, Clausen MR, et al. Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study. Blood Adv. 2025;9:893\u2013905.","journal-title":"Blood Adv"},{"key":"1458_CR73","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood.2021012888","volume":"139","author":"VM Orellana-Noia","year":"2022","unstructured":"Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139:413\u201323.","journal-title":"Blood"},{"key":"1458_CR74","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460\u20138.","journal-title":"Lancet Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01458-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01458-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01458-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:03:01Z","timestamp":1773914581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01458-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1458"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01458-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SMA\u2014Receives research funding for clinical trials from Takeda, Bristol Myers Squibb, Pfizer, AstraZeneca, Affimed, StepPharma, ADC Therapeutics, and Regeneron. GSN\u2014Has a consulting or advisory role for Celgene, MorphoSys, Genentech, Selvita, Debiopharm Group, Kite\/ Gilead, TG Therapeutics, Kymera, Karyopharm Therapeutics, Ryvu Therapeutics, Bantam Pharmaceutical, Bristol Myers Squibb\/Celgene, AbbVie, Genmab, Roche Pharma AG; and receives research funding from Celgene, NanoString Technologies, and MorphoSys.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}